TY  - GEN
AU  - Doi,Toshihiko
AU  - Yoh,Kiyotaka
AU  - Shitara,Kohei
AU  - Takahashi,Hideaki
AU  - Ueno,Makoto
AU  - Kobayashi,Satoshi
AU  - Morimoto,Manabu
AU  - Okusaka,Takuji
AU  - Ueno,Hideki
AU  - Morizane,Chigusa
AU  - Okano,Naohiro
AU  - Nagashima,Fumio
AU  - Furuse,Junji
TI  - First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
SN  - 1573-0646
PY  - 2020///0220
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antimetabolites, Antineoplastic
KW  - pharmacokinetics
KW  - Drug Combinations
KW  - Drug Therapy, Combination
KW  - Enzyme Inhibitors
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasms
KW  - drug therapy
KW  - Oxonic Acid
KW  - Prognosis
KW  - Pyrimidines
KW  - Pyrophosphatases
KW  - antagonists & inhibitors
KW  - Sulfonamides
KW  - Tegafur
KW  - Tissue Distribution
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10637-018-0697-3
ER  -